Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...

Descripción completa

Detalles Bibliográficos

Autores principales:	Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, Giorgio Walter Canonica, MD
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2022-12-01
Colección:	World Allergy Organization Journal
Materias:	Severe asthma Omalizumab Cancer Anti IgE Monoclonal antibodies
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1939455122000977
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!